FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904193863> ?p ?o ?g. }

• W2904193863 abstract "Introduction: Ezetimibe (EZE) is a cholesterol absorption inhibitor and its clinical benefit, as combined with statin for pts with coronary artery disease (CAD), was shown by IMPROVE-IT trial. Campesterol (camp) is the cholesterol absorption marker and the benefit of EZE/statin combination therapy for pts with low camp (LC) value, in whom EZE appears to ineffective, is not clearly understood. The PRECISE-IVUS (Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound) trial was a prospective, randomized, controlled, multicenter study evaluating the effects of EZE addition to atorvastatin (atorva), compared with atorva monotherapy, on coronary atherosclerosis evaluated by IVUS and lipid profile. Hypothesis: In this study, we investigated the effect of EZE for pts with the LC value. Methods: 246 pts undergoing IVUS-guided percutaneous coronary intervention were randomized to EZE/atorva combination (EA) group or atorva alone (A) group. The dosage of atorva was uptitrated with a treatment goal of lowering low-density lipoprotein cholesterol (LDL-C) below 70mg/dL. Serial volumetric IVUS was performed at baseline and 9–12 months follow-up to quantify the coronary plaque response in 202 patients. Results: There were significantly positive correlation between baseline LDL-C level and baseline camp value (R=0.399, p<0.01), but no significant difference between baseline camp value and the presence of prior statin use. Baseline LDL-C level was significantly lower in LC groups (LC group vs. high camp group; 100.2±25.5mg/dL vs. 116.8±23.5mg/dL, respectively, p<0.0001). In the LC group, the delta LDL-C ratio (follow up LDL-C - baseline LDL-C / baseline LDL-C) was significantly lower in EA group compared with A group (-37.2±16.2% vs. -23.4±25.1%, p=0,009) and EA group showed significantly greater reduction in delta percent atheroma volume, compared with A group (-2.2 [-4.1 to -0.1]% vs. -0.3 [-1.6 to 1.1]%, p=0.04). Conclusions: Even in pts with CAD and LC value, statin-EZE combined therapy showed significantly decreased LDL-C and regressed coronary plaque burden. Even if the cholesterol absorption ability is declined, EZE-statin combined therapy might be the promising option for pts with CAD." @default.
• W2904193863 created "2018-12-22" @default.
• W2904193863 creator A5004411843 @default.
• W2904193863 creator A5005316437 @default.
• W2904193863 creator A5007702379 @default.
• W2904193863 creator A5008338537 @default.
• W2904193863 creator A5020090012 @default.
• W2904193863 creator A5020527263 @default.
• W2904193863 creator A5022862433 @default.
• W2904193863 creator A5023792530 @default.
• W2904193863 creator A5024129386 @default.
• W2904193863 creator A5027424299 @default.
• W2904193863 creator A5027915101 @default.
• W2904193863 creator A5036417662 @default.
• W2904193863 creator A5039948252 @default.
• W2904193863 creator A5040904640 @default.
• W2904193863 creator A5055408267 @default.
• W2904193863 creator A5072680574 @default.
• W2904193863 creator A5072918851 @default.
• W2904193863 creator A5075403819 @default.
• W2904193863 creator A5075902668 @default.
• W2904193863 creator A5076087471 @default.
• W2904193863 creator A5079485654 @default.
• W2904193863 creator A5082095133 @default.
• W2904193863 creator A5083422824 @default.
• W2904193863 creator A5084607866 @default.
• W2904193863 creator A5089382635 @default.
• W2904193863 creator A5090067312 @default.
• W2904193863 date "2015-11-10" @default.
• W2904193863 modified "2023-10-01" @default.
• W2904193863 title "Abstract 13048: The Impact of Statin-Ezetimibe Combination Therapy in Patients With Decreased Cholesterol Absorption Ability" @default.
• W2904193863 doi "https://doi.org/10.1161/circ.132.suppl_3.13048" @default.
• W2904193863 hasPublicationYear "2015" @default.
• W2904193863 type Work @default.
• W2904193863 sameAs 2904193863 @default.
• W2904193863 citedByCount "1" @default.
• W2904193863 countsByYear W29041938632018 @default.
• W2904193863 crossrefType "journal-article" @default.
• W2904193863 hasAuthorship W2904193863A5004411843 @default.
• W2904193863 hasAuthorship W2904193863A5005316437 @default.
• W2904193863 hasAuthorship W2904193863A5007702379 @default.
• W2904193863 hasAuthorship W2904193863A5008338537 @default.
• W2904193863 hasAuthorship W2904193863A5020090012 @default.
• W2904193863 hasAuthorship W2904193863A5020527263 @default.
• W2904193863 hasAuthorship W2904193863A5022862433 @default.
• W2904193863 hasAuthorship W2904193863A5023792530 @default.
• W2904193863 hasAuthorship W2904193863A5024129386 @default.
• W2904193863 hasAuthorship W2904193863A5027424299 @default.
• W2904193863 hasAuthorship W2904193863A5027915101 @default.
• W2904193863 hasAuthorship W2904193863A5036417662 @default.
• W2904193863 hasAuthorship W2904193863A5039948252 @default.
• W2904193863 hasAuthorship W2904193863A5040904640 @default.
• W2904193863 hasAuthorship W2904193863A5055408267 @default.
• W2904193863 hasAuthorship W2904193863A5072680574 @default.
• W2904193863 hasAuthorship W2904193863A5072918851 @default.
• W2904193863 hasAuthorship W2904193863A5075403819 @default.
• W2904193863 hasAuthorship W2904193863A5075902668 @default.
• W2904193863 hasAuthorship W2904193863A5076087471 @default.
• W2904193863 hasAuthorship W2904193863A5079485654 @default.
• W2904193863 hasAuthorship W2904193863A5082095133 @default.
• W2904193863 hasAuthorship W2904193863A5083422824 @default.
• W2904193863 hasAuthorship W2904193863A5084607866 @default.
• W2904193863 hasAuthorship W2904193863A5089382635 @default.
• W2904193863 hasAuthorship W2904193863A5090067312 @default.
• W2904193863 hasConcept C126322002 @default.
• W2904193863 hasConcept C164705383 @default.
• W2904193863 hasConcept C168563851 @default.
• W2904193863 hasConcept C2776839432 @default.
• W2904193863 hasConcept C2776931568 @default.
• W2904193863 hasConcept C2777482532 @default.
• W2904193863 hasConcept C2778163477 @default.
• W2904193863 hasConcept C2778213512 @default.
• W2904193863 hasConcept C2778657065 @default.
• W2904193863 hasConcept C2780400711 @default.
• W2904193863 hasConcept C500558357 @default.
• W2904193863 hasConcept C71924100 @default.
• W2904193863 hasConcept C90924648 @default.
• W2904193863 hasConceptScore W2904193863C126322002 @default.
• W2904193863 hasConceptScore W2904193863C164705383 @default.
• W2904193863 hasConceptScore W2904193863C168563851 @default.
• W2904193863 hasConceptScore W2904193863C2776839432 @default.
• W2904193863 hasConceptScore W2904193863C2776931568 @default.
• W2904193863 hasConceptScore W2904193863C2777482532 @default.
• W2904193863 hasConceptScore W2904193863C2778163477 @default.
• W2904193863 hasConceptScore W2904193863C2778213512 @default.
• W2904193863 hasConceptScore W2904193863C2778657065 @default.
• W2904193863 hasConceptScore W2904193863C2780400711 @default.
• W2904193863 hasConceptScore W2904193863C500558357 @default.
• W2904193863 hasConceptScore W2904193863C71924100 @default.
• W2904193863 hasConceptScore W2904193863C90924648 @default.
• W2904193863 hasIssue "suppl_3" @default.
• W2904193863 hasLocation W29041938631 @default.
• W2904193863 hasOpenAccess W2904193863 @default.
• W2904193863 hasPrimaryLocation W29041938631 @default.
• W2904193863 hasRelatedWork W1031089084 @default.
• W2904193863 hasRelatedWork W2038554799 @default.
• W2904193863 hasRelatedWork W2061063342 @default.
• W2904193863 hasRelatedWork W2087737020 @default.
• W2904193863 hasRelatedWork W2157857368 @default.
• W2904193863 hasRelatedWork W2418593364 @default.

• next